	US 12,233,096 B2
	Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells
Wenliang Dong, Almere (NL); Tanja Denise De Gruijl, Amsterdam (NL); Marta López González, Amsterdam (NL); and Victor Willem Van Beusechem, Amstelveen (NL)
Assigned to ORCA Therapeutics B.V., 's-Hertogenbosch (NL)
Appl. No. 17/271,287
Filed by ORCA Therapeutics B.V., s-Hertogenbosch (NL)
PCT Filed Aug. 30, 2019, PCT No. PCT/NL2019/050562 § 371(c)(1), (2) Date Feb. 25, 2021, PCT Pub. No. WO2020/046130, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 18192104 (EP), filed on Aug. 31, 2018.
Prior Publication US 2021/0205383 A1, Jul. 8, 2021
Int. Cl. A61K 35/761 (2015.01); A61K 38/45 (2006.01); C12N 15/86 (2006.01)

CPC A61K 35/761 (2013.01) [A61K 38/45 (2013.01); C12N 15/86 (2013.01); C12N 2710/10332 (2013.01); C12Y 207/11026 (2013.01)]

15 Claims

1. A recombinant replication competent adenovirus comprising in the genome of the adenovirus a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence, wherein the replication competent adenovirus comprises a modification that enables preferential replication of the adenovirus in tumor cells, and wherein the modification comprises:

a mutation in E1A gene, E1B gene or in both genes, and

a promoter for tumor specific expression of E1A or E1B, or a promoter for tissue or cell type specific expression of E1A or E1B.